Xtant Medical (NYSEAMERICAN:XTNT) Shares Cross Above Two Hundred Day Moving Average – Time to Sell?

Shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.00 and traded as high as $0.54. Xtant Medical shares last traded at $0.54, with a volume of 91,934 shares traded.

Xtant Medical Trading Up 12.5 %

The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.88 and a current ratio of 2.12. The firm has a market cap of $75.07 million, a price-to-earnings ratio of -4.15 and a beta of 0.35. The company’s fifty day moving average price is $0.54.

Institutional Trading of Xtant Medical

An institutional investor recently raised its position in Xtant Medical stock. Geode Capital Management LLC raised its stake in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) by 70.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 515,006 shares of the medical device company’s stock after purchasing an additional 212,394 shares during the quarter. Geode Capital Management LLC owned 0.37% of Xtant Medical worth $348,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 69.33% of the company’s stock.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.